First-line regimens with endocrine therapy show benefits in breast cancer

First-line regimens with endocrine therapy show benefits in breast cancer

First-line regimens with endocrine therapy (ET) may be associated with benefits among patients with human epidermal growth factor receptor 2-positive (ERBB2-positive [formerly HER2-positive]) metastatic breast cancer (MBC), according to a study published online Dec. 15 in JAMA Network Open.

Marcela Carausu, M.D., from Institut Curie in Saint-Cloud, France, and colleagues evaluated the association of hormone receptor status and first-line inclusion of ET with outcomes among patients with ERBB2-positive MBC. The analysis used from the French clinical Epidemiological Strategy and Medical Economics cohort of 4,145 patients who started treatment between 2008 and 2017 with follow-up through June 18, 2020.

The researchers observed no significant difference in overall or for 1,520 patients treated with ERBB2-targeted therapy with chemotherapy and with or without ET versus 203 patients receiving ERBB2-targeted therapy with ET. Findings were seen regardless of type of ERBB2-targeted therapy (trastuzumab or trastuzumab with pertuzumab). In propensity-matched patients, results were similar. Among patients with ERBB2-targeted therapy with chemotherapy, those with maintenance ET had significantly better progression-free (hazard ratio, 0.70) and overall survival (hazard ratio, 0.47).

"Our findings suggest that ET-containing regimens may be associated with benefits for a subgroup of patients, suggesting that results from investigating a more personalized approach for these patients may be relevant and necessary," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

More information: Marcela Carausu et al, Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes, JAMA Network Open (2022). DOI: 10.1001/jamanetworkopen.2022.47154

Journal information: JAMA Network Open

Copyright © 2022 HealthDay. All rights reserved.

Citation: First-line regimens with endocrine therapy show benefits in breast cancer (2022, December 20) retrieved 22 April 2024 from https://medicalxpress.com/news/2022-12-first-line-regimens-endocrine-therapy-benefits.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

No benefit seen from adjuvant celecoxib in ERBB2-negative breast cancer

 shares

Feedback to editors